J.P. Morgan Analysts Reiterate Overweight Rating on Abbott Laboratories (ABT) and Raise Price Target Ahead of 3Q20 Earnings Release

On Friday, J.P. Morgan analysts reiterated their Overweight rating on Abbott Laboratories (ABT) while raising their price target from $110 to $125. The analysts give their insight on what they expect to see from 3Q20 results for Abbott Laboratories ahead of earnings season. They like MedTech and Diagnostic businesses combined with BinaxNow, Libre 3.0 and better Fx dynamics.

The analysts forecast 3Q20 revenue sales of $8.70B (+7.8% reported, +8.6%cc) and cash EPS of $0.92 (+9.4%). This is a bit higher than the Street forecast of $8.49B (+7.0%cc) and $0.90 EPS. Similar to the last quarter, better-than-expected COVID trends will work in Abbott’s favor. Medical Devices and Diagnostics is the main factor in representing most of upside given how consensus numbers haven’t moved for recent product announcements (i.e. Binax) and commentary.

J.P. Morgan analysts mentioned, “When combined with the tailwinds the company is seeing within diagnostics from its COVID-19 test approvals,

Read More

Microfluidics Technology Market May See Big Move | Abbott Laboratories, Perkinelmer, Cepheid

Microfluidics Technology Market

A study published on Global Microfluidics Technology Market, includes exploratory survey, qualitative commentary on changing market dynamics with market sizing and estimates for 18+ Global Countries, business segments and applications. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Abbott Laboratories, Perkinelmer, Cepheid, Raindance Technologies, Becton, Dickinson, Bio-Rad Laboratories, Johnson & Johnson, Life Technologies Corporation, Microfluidic Chipshop GMBH & Siemens Healthcare

Get Inside Scoop of the report, request for sample @:https://www.htfmarketreport.com/sample-report/1393262-global-microfluidics-technology-market-3

Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. It also encourages executives and managers to evaluate deeply complementary research metric. The assessments also offer insight into the share and size of varioussegments in the Microfluidics Technology market. The scope of the study includes market break-up or segmentation as follows:

Type:, Silicon-Based Microfluidics, Glass-Based Microfluidics, Polymer-Based Microfluidics &

Read More

Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in vitro diagnostic (IVD) applications.

Under the terms of the agreement, Quanterix will receive an initial license fee, milestone fees subject to the achievement by Abbott of future development, regulatory, and launch milestones and royalties on the sale of licensed products. To learn more about Quanterix, click here.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from

Read More

Analysts Reiterate Overweight Rating on Abbott Laboratories following European Approval of Freestyle Libre 3

On Monday, J.P. Morgan and Morgan Stanley reiterated their Overweight ratings on Abbott Laboratories (ABT). The company’s newest continuous glucose monitor (CGM), the Freestyle Libre 3, recently received a CE mark of approval. The system has shown to be a major evolutionary improvement over the current Libre 2 which leads analysts to believe that there are multiple long-term growth opportunities for Abbott.

The next-gen Libre CGM, Libre 3 will leverage Bluetooth technology to have continuous, real-time glucose readings automatically delivered to your smartphone every-minute (vs user scanning required in the past) allowing for unsurpassed 14-day accuracy and a ~70% size reduction from the Libre 1 & 2, becoming the world’s smallest and thinnest sensor.

The FreeStyle Libre 3 system was designed to fit perfectly into people’s everyday lives, allowing users to check their glucose as often as they like by just looking on their phones. This innovation allows the users

Read More